2024 Q3 Form 10-Q Financial Statement
#000073176624000262 Filed on August 09, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| Revenue | $100.8B | $98.86B |
| YoY Change | 9.16% | 6.41% |
| Cost Of Revenue | $11.83B | $11.34B |
| YoY Change | 25.59% | 16.33% |
| Gross Profit | $88.99B | $87.52B |
| YoY Change | 7.29% | 5.24% |
| Gross Profit Margin | 88.26% | 88.53% |
| Selling, General & Admin | $13.28B | $13.16B |
| YoY Change | -4.15% | -4.69% |
| % of Gross Profit | 14.92% | 15.04% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $1.041B | $1.020B |
| YoY Change | 3.38% | -0.1% |
| % of Gross Profit | 1.17% | 1.17% |
| Operating Expenses | $92.11B | $13.16B |
| YoY Change | 564.83% | -4.69% |
| Operating Profit | $8.708B | $7.875B |
| YoY Change | 2.13% | -2.26% |
| Interest Expense | -$1.074B | $985.0M |
| YoY Change | -228.78% | 18.96% |
| % of Operating Profit | -12.33% | 12.51% |
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | $7.614B | $5.665B |
| YoY Change | -1.01% | -21.64% |
| Income Tax | $1.356B | $1.244B |
| % Of Pretax Income | 17.81% | 21.96% |
| Net Earnings | $6.055B | $4.216B |
| YoY Change | 3.66% | -22.98% |
| Net Earnings / Revenue | 6.01% | 4.26% |
| Basic Earnings Per Share | $6.56 | $4.58 |
| Diluted Earnings Per Share | $6.51 | $4.54 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 923.4M shares | 920.4M shares |
| Diluted Shares Outstanding | 930.0M shares | 928.0M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | ||
| YoY Change | ||
| Cash & Equivalents | $37.13B | $31.32B |
| Short-Term Investments | ||
| Other Short-Term Assets | $7.424B | |
| YoY Change | 26.17% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $20.02B | $23.12B |
| Other Receivables | $27.46B | $26.76B |
| Total Short-Term Assets | $92.26B | $92.04B |
| YoY Change | 0.38% | 318.07% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $10.14B | $9.801B |
| YoY Change | -8.41% | -10.3% |
| Goodwill | $106.0B | $105.4B |
| YoY Change | 4.2% | 3.71% |
| Intangibles | $23.59B | $14.73B |
| YoY Change | 55.22% | -5.84% |
| Long-Term Investments | $48.69B | $46.11B |
| YoY Change | 3377.79% | -8.6% |
| Other Assets | $18.65B | $17.94B |
| YoY Change | 11.61% | 11.64% |
| Total Long-Term Assets | $207.1B | $194.0B |
| YoY Change | 8.88% | -24.84% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $92.26B | $92.04B |
| Total Long-Term Assets | $207.1B | $194.0B |
| Total Assets | $299.3B | $286.1B |
| YoY Change | 6.11% | 2.1% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $30.89B | |
| YoY Change | 4.64% | |
| Accrued Expenses | ||
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $9.900B | |
| YoY Change | 125.0% | |
| Long-Term Debt Due | $3.909B | $11.37B |
| YoY Change | 45.32% | 491.93% |
| Total Short-Term Liabilities | $3.909B | $11.37B |
| YoY Change | -96.58% | -68.27% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $74.10B | $63.73B |
| YoY Change | 27.59% | 7.52% |
| Other Long-Term Liabilities | $82.89B | $79.18B |
| YoY Change | 508.84% | 81.57% |
| Total Long-Term Liabilities | $157.0B | $142.9B |
| YoY Change | 118.98% | 38.91% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $3.909B | $11.37B |
| Total Long-Term Liabilities | $157.0B | $142.9B |
| Total Liabilities | $199.4B | $191.4B |
| YoY Change | 6.03% | -3.25% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | $96.52B | $92.40B |
| YoY Change | 3.59% | 2.67% |
| Common Stock | $9.000M | $9.000M |
| YoY Change | 0.0% | 0.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $99.88B | $94.68B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $299.3B | $286.1B |
| YoY Change | 6.11% | 2.1% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $6.055B | $4.216B |
| YoY Change | 3.66% | -22.98% |
| Depreciation, Depletion And Amortization | $1.041B | $1.020B |
| YoY Change | 3.38% | -0.1% |
| Cash From Operating Activities | $13.96B | $6.481B |
| YoY Change | 102.2% | -41.25% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $991.0M | $853.0M |
| YoY Change | 18.26% | 2.9% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$4.660B | -$6.564B |
| YoY Change | 158.75% | -6599.01% |
| Cash From Investing Activities | -$5.651B | -$7.417B |
| YoY Change | 114.13% | 918.82% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -2.205B | -1.196B |
| YoY Change | -68.96% | -88.56% |
| NET CHANGE | ||
| Cash From Operating Activities | 13.96B | 6.481B |
| Cash From Investing Activities | -5.651B | -7.417B |
| Cash From Financing Activities | -2.205B | -1.196B |
| Net Change In Cash | 6.100B | -2.132B |
| YoY Change | -314.71% | 1275.48% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $13.96B | $6.481B |
| Capital Expenditures | $991.0M | $853.0M |
| Free Cash Flow | $12.97B | $5.628B |
| YoY Change | 113.8% | -44.84% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
921000000 | shares |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q2 | us-gaap |
Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
|
0.50 | rate |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
921000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
924000000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
924000000 | shares |
| us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
809000000 | usd | |
| us-gaap |
Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
|
424000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-13757000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-11748000000 | usd | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
3072000000 | usd | |
| us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
5000000000 | usd | |
| us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
3664000000 | usd | |
| us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
3284000000 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
744000000 | usd | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
628000000 | usd | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
1750000000 | usd | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
2125000000 | usd | |
| us-gaap |
Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
|
8615000000 | usd | |
| us-gaap |
Proceeds From Repayments Of Commercial Paper
ProceedsFromRepaymentsOfCommercialPaper
|
3426000000 | usd | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
5925000000 | usd | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
6394000000 | usd | |
| us-gaap |
Increase Decrease In Deposits
IncreaseDecreaseInDeposits
|
990000000 | usd | |
| us-gaap |
Increase Decrease In Deposits
IncreaseDecreaseInDeposits
|
4069000000 | usd | |
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-753000000 | usd | |
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-1377000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
7035000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
2731000000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-44000000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
106000000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
|
1124000000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
|
18448000000 | usd | |
| unh |
Cash Within Businesses Held For Sale
CashWithinBusinessesHeldForSale
|
-265000000 | usd | |
| unh |
Cash Within Businesses Held For Sale
CashWithinBusinessesHeldForSale
|
0 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
859000000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
18448000000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
25427000000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
23365000000 | usd |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.</span></div> | ||
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</span></div> | ||
| CY2024Q2 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
14000000000 | usd |
| CY2024Q2 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P3Y | |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
47713000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
21000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
44734000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
565000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
0 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
7000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
558000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Amortized Cost Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
|
48278000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain
|
21000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss
|
3007000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Fair Value
DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
|
45292000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
47451000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
134000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2690000000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
44895000000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
603000000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
1000000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
8000000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
596000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Amortized Cost Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityAmortizedCostBeforeAllowanceForCreditLoss
|
48054000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Gain
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedGain
|
135000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Cumulative Unrecognized Loss
DebtSecuritiesAvailableForSaleAndHeldToMaturityCumulativeUnrecognizedLoss
|
2698000000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale And Held To Maturity Fair Value
DebtSecuritiesAvailableForSaleAndHeldToMaturityFairValue
|
45491000000 | usd |
| CY2024Q2 | us-gaap |
Equity Securities Fv Ni And Without Readily Determinable Fair Value
EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
|
4200000000 | usd |
| CY2023Q4 | us-gaap |
Equity Securities Fv Ni And Without Readily Determinable Fair Value
EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
|
4900000000 | usd |
| CY2024Q2 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
1700000000 | usd |
| CY2023Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
1400000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
5172000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
5137000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
|
363000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
|
362000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
14656000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
14021000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
|
171000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
168000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
|
10930000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
|
10044000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
|
14000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After Five Through Ten Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
|
13000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
|
4741000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
|
4432000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsNetCarryingAmount
|
17000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Debt Maturities After Ten Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterTenYearsFairValue
|
15000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
47713000000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
44734000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
565000000 | usd |
| CY2024Q2 | us-gaap |
Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
|
558000000 | usd |
| CY2024Q2 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
|
33000 | |
| CY2024Q2 | us-gaap |
Investment Owned Balance Contracts
InvestmentOwnedBalanceContracts
|
40000 | |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
26286000000 | usd |
| CY2024Q2 | us-gaap |
Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
|
1786000000 | usd |
| CY2024Q2 | unh |
Aarp Assets Under Management
AarpAssetsUnderManagement
|
3414000000 | usd |
| CY2024Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
76220000000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
25427000000 | usd |
| CY2023Q4 | us-gaap |
Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
|
2553000000 | usd |
| CY2023Q4 | unh |
Aarp Assets Under Management
AarpAssetsUnderManagement
|
3755000000 | usd |
| CY2023Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
76630000000 | usd |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
|
0 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
|
0 | usd | |
| CY2024Q2 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
565000000 | usd |
| CY2023Q4 | us-gaap |
Held To Maturity Securities
HeldToMaturitySecurities
|
603000000 | usd |
| unh |
Fair Value Adjustments For Nonfinancial Assets And Liabilities Measured At Fair Value Or Financial Assetsand Liabilities Non Recurring Basis
FairValueAdjustmentsForNonfinancialAssetsAndLiabilitiesMeasuredAtFairValueOrFinancialAssetsandLiabilitiesNonRecurringBasis
|
0 | usd | |
| us-gaap |
Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
|
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of the change in medical costs payable for the six months ended June 30: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical costs payable, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,395 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions (dispositions), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported medical costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reported medical costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,113 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for current year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,887)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,175)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,223)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: medical costs payable included within businesses held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical costs payable, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,547 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,947 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> | ||
| CY2022Q4 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
29056000000 | usd |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
|
1000000 | usd | |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
|
120773000000 | usd | |
| us-gaap |
Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
|
-660000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
|
120113000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
|
91621000000 | usd | |
| us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
|
25602000000 | usd | |
| us-gaap |
Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
|
117223000000 | usd | |
| CY2023Q2 | unh |
Liability For Claims And Claims Adjustment Expense Attributable To Disposal Groups
LiabilityForClaimsAndClaimsAdjustmentExpenseAttributableToDisposalGroups
|
0 | usd |
| CY2023Q2 | us-gaap |
Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
|
31947000000 | usd |
| CY2023Q4 | us-gaap |
Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
|
22300000000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
6000000000 | usd |
| CY2024Q2 | srt |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
35000000 | shares |
| CY2024Q2 | us-gaap |
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
|
44000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
1.88 | |
| CY2024Q1 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
1729000000 | usd |
| CY2024Q2 | us-gaap |
Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
|
2.10 | |
| CY2024Q2 | us-gaap |
Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
|
1935000000 | usd |
| us-gaap |
Other Commitments Description
OtherCommitmentsDescription
|
As of June 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $6 billion | ||
| CY2024Q2 | us-gaap |
Other Commitment
OtherCommitment
|
6000000000 | usd |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
4 | reportablesegments | |
| CY2024Q2 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
997000000 | usd |
| CY2024Q2 | us-gaap |
Revenues
Revenues
|
98855000000 | usd |
| CY2024Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
7875000000 | usd |
| CY2024Q2 | us-gaap |
Interest Expense
InterestExpense
|
985000000 | usd |
| CY2024Q2 | unh |
Loss On Sale Of Subsidiary And Subsidiaries Held For Sale
LossOnSaleOfSubsidiaryAndSubsidiariesHeldForSale
|
-1225000000 | usd |
| CY2024Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
5665000000 | usd |
| CY2023Q2 | us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
1115000000 | usd |
| CY2023Q2 | us-gaap |
Revenues
Revenues
|
92903000000 | usd |
| CY2023Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
8057000000 | usd |
| CY2023Q2 | us-gaap |
Interest Expense
InterestExpense
|
828000000 | usd |
| CY2023Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
7229000000 | usd |
| us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
2008000000 | usd | |
| us-gaap |
Revenues
Revenues
|
198651000000 | usd | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
15806000000 | usd | |
| us-gaap |
Interest Expense
InterestExpense
|
1829000000 | usd | |
| unh |
Loss On Sale Of Subsidiary And Subsidiaries Held For Sale
LossOnSaleOfSubsidiaryAndSubsidiariesHeldForSale
|
-8311000000 | usd | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
5666000000 | usd | |
| us-gaap |
Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
|
1913000000 | usd | |
| us-gaap |
Revenues
Revenues
|
184834000000 | usd | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
16143000000 | usd | |
| us-gaap |
Interest Expense
InterestExpense
|
1582000000 | usd | |
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
14561000000 | usd | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
